Titan Completes Preclinical Study of a Continuous, Dopamine Agonist Treatment for Parkinson's Disease July 9, 2012
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2012 Financial Results May 9, 2012
Titan Pharmaceuticals Announces Phase 3 Probuphine(R) Data Presentation at the American Society of Addiction Medicine (ASAM) 43rd Medical-Scientific Conference April 20, 2012
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2011 Financial Results March 14, 2012
Titan Pharmaceuticals to Participate in RBC Capital Markets Global Healthcare Conference February 23, 2012
Titan Pharmaceuticals Announces Positive Results of Six-Month Open-Label Safety Retreatment Study of Probuphine February 9, 2012
